肝癌作为全球范围内最常见的恶性肿瘤之一,其治疗一直是医学研究的重点。近年来,干细胞研究逐渐成为热点,特别是在治疗晚期肝病领域,干细胞疗法已经取得了显著成就。然而,其在肝癌治疗领域的应用研究相对较少,其安全性问题尚需深入探究。本综述旨在探讨骨髓间充质干细胞(BMSCs)在肝癌治疗中的临床和实验研究现状。As one of the most common malignant tumors in the world, the treatment of liver cancer has been the focus of medical research. In recent years, stem cell research has gradually become a hot spot, especially in the treatment of advanced liver disease, stem cell therapy has made remarkable achievements. However, its application in the field of liver cancer treatment is relatively few, and its safety needs to be further explored. This review aims to investigate the clinical and experimental research status of Bone mesenchymal stem cells (BMSCs) in the treatment of liver cancer.
间充质干细胞(MSC),也称为多能基质细胞,是一种首次在骨髓中发现的非造血干细胞群,目前已从各种成体组织来源中分离出来,是能够分化为多种间充质组织(如脂肪和骨骼)的成熟细胞的多能细胞。MicroRNAs (miRNA)是一种高度保守的内源性非蛋白质编码RNA,通过翻译抑制或降解其靶标来调节基因表达,在调节BMSC分化中起主要作用。本文探讨了miRNAs骨髓间充质干细胞成骨分化中的作用。Mesenchymal stem cells (MSCs), also known as pluripotent stromal cells, are a population of non-hematopoietic stem cells first discovered in the bone marrow that have been isolated from various adult tissue sources and are pluripotent cells capable of differentiating into mature cells of a variety of mesenchymal tissues, such as fat and bone. MicroRNAs (miRNAs) are highly conserved endogenous non-protein-coding RNAs that play a major role in regulating BMSC differentiation by translating inhibition or degradation of their targets to regulate gene expression. This article explores the role of miRNAs in osteogenic differentiation of bone marrow mesenchymal stem cells.
